BR112016000612B8 - Uso de leite na fabricação de uma composição para prevenir ou reduzir os sintomas de intolerância a lactose - Google Patents

Uso de leite na fabricação de uma composição para prevenir ou reduzir os sintomas de intolerância a lactose

Info

Publication number
BR112016000612B8
BR112016000612B8 BR112016000612A BR112016000612A BR112016000612B8 BR 112016000612 B8 BR112016000612 B8 BR 112016000612B8 BR 112016000612 A BR112016000612 A BR 112016000612A BR 112016000612 A BR112016000612 A BR 112016000612A BR 112016000612 B8 BR112016000612 B8 BR 112016000612B8
Authority
BR
Brazil
Prior art keywords
composition
lactose intolerance
milk
manufacture
prevent
Prior art date
Application number
BR112016000612A
Other languages
English (en)
Other versions
BR112016000612B1 (pt
BR112016000612A2 (pt
Inventor
John Clarke Andrew
Suchin Trivedi Malav
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52280344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016000612(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of BR112016000612A2 publication Critical patent/BR112016000612A2/pt
Publication of BR112016000612B1 publication Critical patent/BR112016000612B1/pt
Publication of BR112016000612B8 publication Critical patent/BR112016000612B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

beta-caseína a2 e redução ou prevenção de sintomas de intolerância à lactose a presente invenção se refere à prevenção ou redução dos sintomas de intolerância à lactose em um animal, compreendendo o consumo pelo animal de uma composição que contenha beta-caseína, ou de se fornecer a composição ao animal para consumo, em que a beta-caseína compreende pelo menos 75% em peso de beta-caseína a2. o efeito é tanto agudo (pós exposição à composição) quanto permanente (futura exposição à lactose).
BR112016000612A 2013-07-12 2014-07-10 Uso de leite na fabricação de uma composição para prevenir ou reduzir os sintomas de intolerância a lactose BR112016000612B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845480P 2013-07-12 2013-07-12
US61/845,480 2013-07-12
PCT/NZ2014/000141 WO2015005804A1 (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Publications (3)

Publication Number Publication Date
BR112016000612A2 BR112016000612A2 (pt) 2017-07-25
BR112016000612B1 BR112016000612B1 (pt) 2021-11-03
BR112016000612B8 true BR112016000612B8 (pt) 2022-02-22

Family

ID=52280344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016000612A BR112016000612B8 (pt) 2013-07-12 2014-07-10 Uso de leite na fabricação de uma composição para prevenir ou reduzir os sintomas de intolerância a lactose

Country Status (21)

Country Link
US (3) US20160136238A1 (pt)
EP (2) EP3019180B1 (pt)
JP (2) JP6436592B2 (pt)
KR (2) KR102367941B1 (pt)
CN (3) CN105431156A (pt)
AU (2) AU2014287862B2 (pt)
BR (1) BR112016000612B8 (pt)
CA (2) CA3214545A1 (pt)
CL (1) CL2016000064A1 (pt)
DK (1) DK3019180T3 (pt)
ES (1) ES2743194T3 (pt)
HK (1) HK1223846A1 (pt)
IL (2) IL243366B (pt)
MX (2) MX368912B (pt)
MY (2) MY172939A (pt)
NZ (2) NZ754642A (pt)
PH (2) PH12016500032B1 (pt)
RU (1) RU2671562C2 (pt)
SG (2) SG11201510707YA (pt)
WO (1) WO2015005804A1 (pt)
ZA (1) ZA201600007B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190750A1 (en) * 2015-05-22 2016-12-01 The A2 Milk Company Limited Beta-casein a2 and antioxidant capacity
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
JP7394527B2 (ja) 2016-03-30 2023-12-08 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および認知機能
US11925197B2 (en) 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69536000D1 (de) 1994-11-04 2009-10-22 A2 Corp Ltd Selektionsverfahren für nicht-diabetogene milch oder milchprodukte sowie hierdurch erfasste milch oder milchprodukte
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
CA2217820C (en) 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
EP1196047A4 (en) * 1999-06-29 2004-12-22 New Zealand Milk Inst Ltd MILK-BASED PROPHYLACTIC FOOD SUPPLEMENTS
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
HUE044812T2 (hu) * 2003-09-23 2019-11-28 Dsm Ip Assets Bv Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
CN1899054A (zh) * 2006-07-17 2007-01-24 颜贻谦 去糖牛奶的制作方法
CA2756765A1 (en) * 2009-04-03 2010-10-07 Nestec S.A. Milk-like beverages
AU2010238184B2 (en) * 2009-04-15 2014-09-04 Glanbia Nutritionals (Ireland) Limited A reduced lactose milk product and a process for the preparation thereof
DE102010009582A1 (de) * 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
CN103315063A (zh) * 2012-03-19 2013-09-25 基斯有限公司 可预防疾病的婴儿配方奶粉
CN106455662A (zh) * 2014-06-03 2017-02-22 雅培制药有限公司 包含亲脂性活性成分的营养组合物

Also Published As

Publication number Publication date
SG10201710237PA (en) 2018-01-30
CA2917492A1 (en) 2015-01-15
KR20200085375A (ko) 2020-07-14
US20160136238A1 (en) 2016-05-19
JP2016523958A (ja) 2016-08-12
EP3019180A4 (en) 2017-03-08
MY172939A (en) 2019-12-16
CN110800803A (zh) 2020-02-18
JP2018203753A (ja) 2018-12-27
BR112016000612B1 (pt) 2021-11-03
US20220175882A1 (en) 2022-06-09
EP3019180B1 (en) 2019-05-29
RU2671562C2 (ru) 2018-11-02
PH12019550112A1 (en) 2020-09-14
KR102367941B1 (ko) 2022-02-24
SG11201510707YA (en) 2016-01-28
AU2019203684A1 (en) 2019-06-20
KR20160030974A (ko) 2016-03-21
DK3019180T3 (da) 2019-08-26
AU2019203684B2 (en) 2021-08-05
ES2743194T3 (es) 2020-02-18
EP3019180A1 (en) 2016-05-18
MX2019012446A (es) 2020-02-03
EP3542805A1 (en) 2019-09-25
NZ754642A (en) 2022-09-30
RU2018131604A (ru) 2018-11-20
AU2014287862A1 (en) 2016-02-11
NZ715985A (en) 2022-09-30
BR112016000612A2 (pt) 2017-07-25
CN105431156A (zh) 2016-03-23
RU2018131604A3 (pt) 2022-04-19
HK1223846A1 (zh) 2017-08-11
CA3214545A1 (en) 2015-01-15
AU2014287862B2 (en) 2019-07-11
KR102291660B1 (ko) 2021-08-19
CA2917492C (en) 2023-11-14
RU2015156804A3 (pt) 2018-05-31
PH12016500032A1 (en) 2016-03-28
US20200147173A1 (en) 2020-05-14
ZA201600007B (en) 2017-11-29
IL243366B (en) 2018-11-29
CN114832092A (zh) 2022-08-02
RU2015156804A (ru) 2017-08-17
PH12016500032B1 (en) 2016-03-28
JP6990154B2 (ja) 2022-01-12
MX368912B (es) 2019-10-21
IL261143A (en) 2018-10-31
MY190309A (en) 2022-04-13
WO2015005804A1 (en) 2015-01-15
MX2016000308A (es) 2016-11-14
IL261143B (en) 2021-02-28
JP6436592B2 (ja) 2018-12-12
CL2016000064A1 (es) 2016-12-16

Similar Documents

Publication Publication Date Title
BR112016000612B8 (pt) Uso de leite na fabricação de uma composição para prevenir ou reduzir os sintomas de intolerância a lactose
BR112015029987A2 (pt) beta-caseína a2 e a prevenção de inflamação do intestino
BR112017017217A2 (pt) ?composição que compreende ramnolipídeo e siloxano?
BR112015027280A8 (pt) nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
BR112016024508A2 (pt) emulsão, processo para preparação de uma emulsão, e, uso de uma emulsão
UY35262A (es) Proceso para la preparación de oxiranos y triazoles sustituidos
BR112018011216A2 (pt) métodos para inibir a conversão de colina em trimetilamina (tma)
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
BRPI1011516A8 (pt) Aglomerado de pelo menos uma partícula p, processo para a produção de aglomerados, e, uso dos aglomerados.
BR112015025787A8 (pt) composição para o tratamento e/ou pós-tratamento do câncer e uso de uma combinação de óleo de peixe e suco na fabricação de tal composição
BR112015022092A8 (pt) derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
BR112012024359A2 (pt) contorção de um aparelho eletrônico
BR112017012648A2 (pt) composição oral ou tópica e uso de um agonista de fator nuclear eritróide 2 relacionado ao fator 2 e um agonista do receptor hepático x como agentes ativos em uma composição oral ou tópica para beneficiar o crescimento da fibra capilar e/ou induzir o elemento de resposta antioxidante (are)
BR112018068817A2 (pt) beta-caseínas e função cognitiva
MX363853B (es) Una formulación de aceite marino que comprende resveratrol o sus derivados para su uso en el tratamiento, retraso y/o prevención de la enfermedad de alzheimer.
BR112015019220A2 (pt) uso de um inibidor de helicase-primase; uso de uma composição farmacêutica; e composição farmacêutica
BR112015018180A2 (pt) composição estereoisomérica de difenoconazol com fitotoxicidade reduzida
BR112013030308A2 (pt) composição de oligossacarídeos para prevenir ou reduzir o risco de síndrome metabólica
BR112014022921B8 (pt) Composição farmacêutica compreendendo veneno paralizante de moluscos e uso do mesmo.
BR112015030202A2 (pt) composições para alvejamento de polpa e uso das mesmas
BR112018067602A2 (pt) ambrisentan para uso no tratamento de insuficiência renal aguda
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
BR112015024181A2 (pt) uso de uma composição compreendendo silibina
BR112019001178A2 (pt) biotinas e composição de biotina
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: THE A2 MILK COMPANY LIMITED (NZ)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2652 DE 03/11/2021 QUANTO AO INVENTOR.